The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies.

Sadeghi Rad, H; Bazaz, SR; Monkman, J; Ebrahimi Warkiani, M; Rezaei, N; O'Byrne, K; Kulasinghe, A

The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies.

Sadeghi Rad, H Bazaz, SR Monkman, J Ebrahimi Warkiani, M

Rezaei, N O'Byrne, K Kulasinghe, A

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Clinical & translational immunology, 2020, 9, (11)
Issue Date:: 2020-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (1.24 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Sadeghi Rad, H
dc.contributor.author	Bazaz, SR
dc.contributor.author	Monkman, J
dc.contributor.author	Ebrahimi Warkiani, M https://orcid.org/0000-0002-4184-1944
dc.contributor.author	Rezaei, N
dc.contributor.author	O'Byrne, K
dc.contributor.author	Kulasinghe, A
dc.date.accessioned	2021-03-05T03:32:41Z
dc.date.available	2020-10-25
dc.date.available	2021-03-05T03:32:41Z
dc.date.issued	2020-01
dc.identifier.citation	Clinical & translational immunology, 2020, 9, (11)
dc.identifier.issn	2050-0068
dc.identifier.issn	2050-0068
dc.identifier.uri	http://hdl.handle.net/10453/146811
dc.description.abstract	Immunotherapies have shown long-lasting and unparalleled responses for cancer patients compared to conventional therapy. However, they seem to only be effective in a subset of patients. Therefore, it has become evident that a greater understanding of the tumor microenvironment (TME) is required to understand the nuances which may be at play for a favorable outcome to therapy. The immune contexture of the TME is an important factor in dictating how well a tumor may respond to immune checkpoint inhibitors. While traditional immunohistochemistry techniques allow for the profiling of cells in the tumor, this is often lost when tumors are analysed using bulk tissue genomic approaches. Moreover, the actual cellular proportions, cellular heterogeneity and deeper spatial distribution are lacking in characterisation. Advances in tissue interrogation technologies have given rise to spatially resolved characterisation of the TME. This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated with a favorable outcome to immunotherapy.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	Clinical & translational immunology
dc.relation.isbasedon	10.1002/cti2.1215
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1107 Immunology, 1115 Pharmacology and Pharmaceutical Sciences
dc.title	The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies.
dc.type	Journal Article
utslib.citation.volume	9
utslib.location.activity	Australia
utslib.for	1107 Immunology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2021-03-05T03:32:38Z
pubs.issue	11
pubs.publication-status	Published
pubs.volume	9
utslib.citation.issue	11

Abstract:

Immunotherapies have shown long-lasting and unparalleled responses for cancer patients compared to conventional therapy. However, they seem to only be effective in a subset of patients. Therefore, it has become evident that a greater understanding of the tumor microenvironment (TME) is required to understand the nuances which may be at play for a favorable outcome to therapy. The immune contexture of the TME is an important factor in dictating how well a tumor may respond to immune checkpoint inhibitors. While traditional immunohistochemistry techniques allow for the profiling of cells in the tumor, this is often lost when tumors are analysed using bulk tissue genomic approaches. Moreover, the actual cellular proportions, cellular heterogeneity and deeper spatial distribution are lacking in characterisation. Advances in tissue interrogation technologies have given rise to spatially resolved characterisation of the TME. This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated with a favorable outcome to immunotherapy.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/146811